Effect of Methylprednisolone on treatment of COVID-19

Phase 2

• Conditions: COVID-19 disease.; COVID-19; U07.2, U07

• Registration Number: IRCT20200404046947N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 15 June 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 68

Inclusion Criteria

COVID-19 patient confirmed by positive PCR ?test for SARS-CoV-2 or abnormal CT scan finding (bilateral, sub pleural, peripheral ground glass ?opacities), Blood oxygen saturation <93%, Respiratory Rate >30 breaths/minute, before connecting to ventilator and intubation.?

Exclusion Criteria

Patients with uncontrolled type I diabetes, blood pressure, positive pro-calcitonin, active infection, and ?taking any immune-suppressor agents, will exclude from the study.?

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Radiographic features Findings. Timepoint: Before and at discharge time only in patients agreed ?to give informed consent. Method of measurement: CT scan.;Mortality rate. Timepoint: Before and after. Method of measurement: Observation.;O2 saturation. Timepoint: Before and after ( by 3 days of treatment and at discharge). Method of measurement: Pulse Oximeter.;Need an oxygen therapy ?. Timepoint: Before and after (at day 3 and discharge time). Method of measurement: clinical.

Secondary Outcome Measures

Name	Time	Method
aboratory tests. Timepoint: Before and after (at day 3, and discharge time). Method of measurement: Para-clinical.